학술논문
First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) vs. VAD as Induction Treatment Prior to High-dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM): B152
Document Type
Academic Journal
Author
Sonneveld, P; Eljarari, L; Salwender, H; Zweegman, S; Vellenga, E; Van Der Holt, B; Schmidt-Wolf, I GH; Bertsch, U; Schubert, J; Blau, I W; Jie, G SK; Beverloo, B; Jauch, A; Hose, D; Schaafsma, R; Kersten, M J; Delforge, M; De Weerdt, O; Van Der Griend, R; Wijermans, P W; Martin, H; Van Der Velde, H; Lokhorst, H M; Goldschmidt, H
Source
Clinical Lymphoma & Myeloma. Feb 01, 2009 9 Sup 1:S105-S106
Subject
Language
English
ISSN
1557-9190